ChemicalBook > Product Catalog >API >Antineoplastic agents >Tinib Antineoplastic drugs >Erlotinib hydrochloride

Erlotinib hydrochloride

Erlotinib hydrochloride Suppliers list
Company Name: Beijing Cooperate Pharmaceutical Co.,Ltd
Tel: 010-60279497
Products Intro: Product Name:Erlotinib hydrochloride
Purity:98% Package:100G;1KG;5KG;10KG;25KG;50KG;100KG
Company Name: Shanghai Payne Pharmatech Ltd.
Tel: 021-58123769
Products Intro: Product Name:Erlotinib-11
Purity:95+% HPLC Package:10mg;25mg;50mg;100mg
Company Name: Chongqing Chemdad Co., Ltd
Tel: +86-13650506873
Products Intro: Product Name:Erlotinib hydrochloride
Purity:0.98 Package:1kg,2kg,5kg,10kg,25kg
Company Name: Frapp's ChemicalNFTZ Co., Ltd.
Tel: +86 (576) 8169-6106
Products Intro: Product Name:Erlotinib hydrochloride
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Products Intro: Product Name:Erlotinib hydrochloride
Purity:99% Package:100g,500g,1KG,10KG,100KG

Lastest Price from Erlotinib hydrochloride manufacturers

  • Erlotinib hydrochloride
  • US $0.00-0.00 / KG
  • 2020-07-22
  • CAS:183319-69-9
  • Min. Order: 1g
  • Purity: 99.0%
  • Supply Ability: 200kg/month
  • Erlotinib hydrochloride
  • US $8300.00 / KG
  • 2019-07-06
  • CAS:183319-69-9
  • Min. Order: 1KG
  • Purity: 99%
  • Supply Ability: 20tons
Erlotinib hydrochloride Basic information
Indications and Usage Mechanisms of Action Clinical Research
Product Name:Erlotinib hydrochloride
Synonyms:ERLOTINIB HCL;ERLOTINIB HCL SALT;ERLOTINIB HCL SALT :TARCEVA;Erlotinib, Hydrochloride Salt;N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, Hydrochloride Salt, OSI 774, Tarceva; N-(3-Ethynylphenyl)-6,7-bis-(2-methoxyethoxy)-quinazolin-4-amine;[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4yl]-(3-ethynyl-phenyl)-amine;Tarceva Hydrochloride See E625000
Product Categories:Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Heterocyclic Compounds;anti-neoplastic;Anti-cancer&immunity;Antineoplastic;Tarceva;Inhibitors;Molecular Targeted Antineoplastic;API
Mol File:183319-69-9.mol
Erlotinib hydrochloride Structure
Erlotinib hydrochloride Chemical Properties
Melting point 223-225°C
storage temp. -20°C Freezer
pkapKa (25°): 5.42
form Yellow powder.
CAS DataBase Reference183319-69-9(CAS DataBase Reference)
Safety Information
Safety Statements 24/25
HS Code 29335990
MSDS Information
Erlotinib hydrochloride Usage And Synthesis
Indications and UsageErlotinib hydrochlorate is a small molecule tyrosine kinase inhibitor which acts reversibly on epidermal growth factor receptors, a hydrochloride of erlotinib, a molecular-targeted drug. The US Food and Drug Administration (FDA) has approved erlotinib (Tarceva) combined with gemcitabine as a first-line treatment for locally advanced and metastatic pancreatic cancer.
It is mainly used as a second- or third-line treatment for locally advanced or metstatic non-small cell lung cancer (NSCLC) and as a treatment for pancreatic cancer. It is used as a tyrosine inhibitor for NSCLC treatment.
Mechanisms of ActionThe small molecular compound erlotinib is a tyrosine kinase receptor inhibitor which inhibits the proliferation of tumor cells by inhibiting phosphorylation, binding to the intracellular catalytic domain of tyrosine kinase in competition with ATP, thus blocking downstream signal transduction and inhibiting activity of tumor cell ligand dependent HER-1/EGFR.
Clinical ResearchPhase I clinical trials showed that the main toxicities and side effects of erlotinib were dose-dependent rashes and diarrhea. Other rare side effects included headaches, nausea, and vomiting. Phase II trials used erlotinib as a second-line anticancer drug, with efficacy matching second-line chemotherapy drug docetaxel. Phase III randomized control trials (BR21) mainly focused on NSCLC patients (locally advanced and distant metastasis) after the failure of first- or second-line chemotherapy. The treatment group, with 488 cases in total, took 150mg of erlotinib daily. The control group (243 cases) took a placebo. The study showed:
Median survival rate: 6.7 months for the treatment group, 4.7 months for the control (P<0.001, hazard ratio HR=0.73)
1 year survival rate: 31.2% for the treatment group, 21.5% for the control
Median time of no progression: 9.9 weeks for the treatment group, 7.9 weeks for the control
Meanwhile, symptomatic improvement in the treatment group was more pronounced.
Based on the results of the BR21 study, several further phase III clinical trials were conducted. The TRIBUTE trial combined erlotinib with chemotherapy. The treatment group used chemotherapy (carboplatin + paclitaxel) + erlotinib, while the control used the same chemotherapy alone, with a total of 1,059 late-stage NSCLC patients. The effectiveness of the treatment group was 21.5%, and the control group 19.3%; median survival times were 10.8 and 10.6 months, respectively, and the times of tumor progression (TTP) were 5.1 and 5.0 months. Meanwhile, TALENT trials, with 1,172 NSCLC patients, also investigated the effects of adding erlotinib to chemotherapy (gemcitabine + cisplatin), and also failed to show that erlotinib significantly increased its effects.
DescriptionErlotinib, launched as once daily oral treatment for patients with non-small-cell lung cancer (NSCLC), is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, and it is the second small-molecule drug to be marketed with this mechanism of action. Both erlotinib and its predecessor, gefitinib, are members of the anilinoquinazoline class of tyrosine kinase inhibitors. They compete with the binding of ATP to the intracellular tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and blocking downstream signal transduction. Erlotinib is prepared by the condensation of 3-ethynylaniline with 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline, which is a key intermediate obtained in five synthetic steps starting from ethyl 3,4- dihydroxybenzoate. In vitro, Erlotinib inhibits purified human EGFR tyrosine kinase with an IC50 of 2 nM and blocks EGFR autophosphorylation in cellular assays with an IC50 of 20nM. Treatment of human colon cancer cells with erlotinib was associated with growth inhibition, G1 cell cycle arrest, and apoptosis. Oral administration of erlotinib in athymic mice produced potent antitumor effects with an ED50 of 9.2 mg/kg/day for HN5 head and neck xenografts and 14 mg/ kg/day for A431 epidermoid xenografts. The absorption of Erlotinib following oral dosing is approximately 60%. Food greatly enhances the absorption allowing for almost 100% bioavailability of the dose. The time to reach peak plasma levels of the drug is about 4 hours, and the half-life is approximately 36 hours. Steady-state drug levels are reached in 7 to 8 days. Erlotinib has high protein binding (93%) and has an apparent volume of distribution of 232 L. It is metabolized primarily by CYP3A4 and to a lesser extent by CYP1A2 and CYP1A1. The drug is mainly excreted in the feces with less than 9% of the dose found in the urine. Erlotinib is labeled for the treatment of patients with locally advanced or metastatic NSCLC who have failed one or more previous chemotherapy regimens. The recommended dosage is 150 mg daily until disease progression is detected. In a randomized, double blind, placebo-controlled trial involving 731 patients, 150 mg/day oral dose of erlotinib resulted in a median overall survival of 6.7 months compared with 4.7 months in the placebo group (p<0.001). Progression-free survival was 9.9 weeks and 7.9 weeks in the erlotinib and placebo groups, respectively (p<0.001). Survival at one year was 31.2% in the erlotinib group versus 21.5% in the placebo group. The use of erlotinib showed greater benefit in patients with EGFR positive tumors and in those who never smoked. The most common adverse events reported in clinical trials were rash (9%) and diarrhea (6%). Elevations in liver function tests were also seen; however, these effects were mainly transient or associated with liver metastases. As previously noted for gefitinib, erlotinib is also shown to lack any clinical benefit in concurrent administration with platinum-based chemotherapy.
Chemical PropertiesOff-White Solid
OriginatorPfizer (US)
UsesSelective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor. Antineoplastic
UsesErlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM.
UsesErlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Phase 3.
DefinitionChEBI: A quinazoline hydrochloride compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions.
Brand nameTarceva (OSI).
General DescriptionErlotinib is available as 25-, 100-, and 150-mg tablets fororal administration and is used after failure of first-linetherapy in metastatic NSCLC and as first-line therapy incombination with gemcitabine in the treatment of metastaticpancreatic cancer, and in treating malignant gliomas.The structural similarity to gefitnib imparts similar pharmacokineticbehavior with bioavailability of 60% and proteinbinding of 93%. The agent is extensively metabolizedprimarily by CYP3A4. Three major metabolic pathwayshave been identified, involving oxidative-O-demethylationof the side chains followed by further oxidation to give thecarboxlic acids, oxidation of the acetylene functionalityto give a carboxylic acid, and aromatic hydroxylation ofthe phenyl ring para to the electron-donating nitrogen. Themetabolites are primarily eliminated in the feces, and theterminal half-life is 36 hours.The major toxicities seenwith the agent are dose-limiting skin rash and diarrhea.Other common adverse effects include shortness of breath,fatigue, and nausea.
Erlotinib hydrochloride Preparation Products And Raw materials
Tag:Erlotinib hydrochloride(183319-69-9) Related Product Information
Erlotinib Triethylamine (Trifluoromethoxy)benzene Anisole Topotecan hydrochloride Guaiacol Bis(2-ethylhexyl)amine Ethoxyquin Triethanolamine Ethoxyethyne 4-Methoxyphenol ERLOTINIB-D6, HYDROCHLORIDE SALT Desmethyl Erlotinib Acetate ERLOTINIB MESYLATE Erlotinib hydrochloride Nilotinib Ethoxyamine hydrochloride p-Anisaldehyde